We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksR&Q Insurance Regulatory News (RQIH)

Share Price Information for R&Q Insurance (RQIH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.26
Bid: 2.15
Ask: 2.27
Change: -0.30 (-11.95%)
Spread: 0.12 (5.581%)
Open: 2.26
High: 2.26
Low: 2.26
Prev. Close: 2.51
RQIH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Proposed Sale of Accredited

14 Nov 2023 07:00

RNS Number : 3010T
R&Q Insurance Holdings Ltd
14 November 2023
 

 

 

 

R&Q Insurance Holdings Limited

 

Update on Proposed Sale of Accredited

 

14 November 2023

 

On 20 October 2023, R&Q Insurance Holdings Ltd (AIM-RQIH) ("R&Q") announced the proposed Sale of Accredited to Onex Corporation (the "Announcement"). Capitalised terms used, but not defined, in this announcement have the meaning given to such terms in the Announcement. The full announcement can be found here: https://www.rqih.com/news

 

As explained in the Announcement, the transaction is conditional on R&Q shareholder and regulatory approval as well as customary consents from certain R&Q debt providers. R&Q continues to work expediently towards satisfying these conditions and closing of the Sale is expected to occur in late Q1 2024 or early Q2 2024.

 

In the Announcement, R&Q provided a brief summary of its future strategy for R&Q Legacy, on the assumption that the Sale achieves a successful conclusion. Although completion of the Sale continues to be conditional on the factors noted above, the Board recognises shareholders' interest in better understanding the profile of R&Q Legacy as a standalone business. Accordingly, R&Q today announces the publication of a presentation on R&Q Legacy (the "Presentation") which can be found on R&Q's website via the link:

 

https://www.rqih.com/investors/shareholder-information/investor-presentations/

 

The Presentation provides further detail on R&Q's envisaged strategy, market position and financial objectives as a refocused global legacy company, should the Sale successfully close.

 

As previously announced, upon closing of the Sale, Jeff Hayman will act as Chairman and Interim Chief Executive Officer of R&Q and Paul Bradbrook, currently Chief Accounting Officer of R&Q, will become Chief Financial Officer of R&Q and a member of the Board, subject to customary approvals. The Presentation also outlines R&Q Legacy's wider management team and its significant collective experience. The management team is excited by the growth opportunity it sees within R&Q Legacy's addressable market. In the Presentation, management has set out three strategic priorities through which it believes R&Q Legacy can deliver growth and value creation:

· Grow fee income

· Reduce expenses

· Decrease balance sheet volatility

 

Underpinning these priorities are strategic initiatives currently underway to de-risk the R&Q Legacy portfolio including:

· A possible LPT (Loss Portfolio Transfer) or ADC (Adverse Development Cover) on certain portfolios

· The sale of non-core assets

· The sale, or securitization, of back book legacy liabilities

 

In the Presentation, R&Q provides an associated plan for the R&Q Legacy business, although it should be stressed that the ability of R&Q Legacy to achieve such objectives depends on many factors, including not least a successful closing of the Sale and the paydown of R&Q debt. This plan includes that:

· The refocused business and strategy is expected to deliver operating profitability by full year 2025

· Fee income is targeted to be doubled in 2025 compared to H1 2023 annualised

· Expenses are anticipated to be reduced by 15% to 20% in 2025 relative to an adjusted annualised H1 2023 expense base that includes certain assumptions around Legacy's standalone cost structure

· As R&Q returns to profitability, it will review its dividend policy, subject to constraints due to relationships with lenders, regulators and preferred shareholders

 

The Presentation also outlines R&Q's expectation of $100m+ of cumulative surplus capital to be generated over the next ~5 years as claims payments are made, releasing capital held against reserves. This is in addition to the estimated $40m - $80m of additional collateral R&Q will be required to hold against existing legacy exposure retained by Accredited, which R&Q expects to be released and available over the next 5+ years as the underlying exposures are reduced and eliminated.

 

Jeff Hayman, Chairman of R&Q, said: "We recognise the importance of giving our shareholders a clear vision around R&Q's future as a refocused global legacy company, should the proposed Sale of Accredited to Onex achieve a successful conclusion. The Presentation further outlines our belief that R&Q can build significant value as a standalone legacy business and the clear strategy we have to return the business to operating profitability, materially reduce balance sheet volatility and establish a stronger capital position. Building our Reserves Under Management is an important part of this strategy, and we have also provided detail on the strength of our management team and their extensive experience in non-life run-off, our large and addressable market opportunity and the active nature of our pipeline. We look forward to continuing to engage with all of our stakeholders."

 

As stated above, the plan is based on many assumptions, including shareholder and regulatory approvals of our proposed Sale and consent from our lenders. A more detailed explanation of the Sale is included in our announcement of 20 October 2023. The Presentation should be read in conjunction with that announcement.

 

Ends

 

Enquiries to:

R&Q Insurance Holdings Ltd Tel: +44 (0)20 7780 5850

Jeff Hayman

William Spiegel

Tom Solomon

 

Fenchurch Advisory Partners LLP (Financial Adviser) Tel: +44 (0)20 7382 2222

Kunal Gandhi

Brendan Perkins

John Sipp

Richard Locke

Tihomir Kerkenezov

 

Barclays Bank PLC (Financial Adviser and Joint Broker) Tel: +44 (0)20 7632 2322

Gary Antenberg

Richard Bassingthwaighte

Grant Bickwit

 

Howden Tiger (Financial Adviser) Tel : +44 (0)20 7398 4888

Rob Bredahl

Leo Beckham

 

Deutsche Numis (Nominated Adviser and Joint Broker) Tel : +44 (0)20 7260 1000

Charles Farquhar

Giles Rolls

 

FTI Consulting Tel: +44 (0)20 3727 1051

Tom Blackwell

 

 

 

Notes to Editors:

 

About R&Q

 

R&Q is a global non-life specialty insurance company. We operate two core businesses: Program Management and Legacy Insurance. Both these businesses are leaders in their respective markets.

 

Our approach is to deploy our origination and underwriting capabilities, alongside our licensed and rated carriers in the US, EU, and the UK, to generate attractive fee returns in Program Management and Legacy Insurance.

 

Legal Entity Identifier (LEI): 2138006K1U38QCGLFC94

 

Website: www.rqih.com

 

Forward-Looking Statements

 

This announcement contains forward-looking statements with respect to R&Q and its industries, that reflect its current views with respect to future events and financial performance. Statements that are not historical facts, including statements about R&Q's beliefs, plans or expectations, are forward-looking statements. These statements are based on current plans, estimates and expectations, all of which involve risk and uncertainty. Statements that include the words "expect," "intend," "plan," "believe," "project," "anticipate," "may", "could" or "would" or similar statements of a future or forward-looking nature identify forward-looking statements. Actual results may differ materially from those included in such forward-looking statements and therefore you should not place undue reliance on them.

 

A non-exclusive list of the important factors that could cause actual results to differ materially from those in such forward-looking statements includes: (a) changes in the size of claims relating to natural or man-made catastrophe losses due to the preliminary nature of some reports and estimates of loss and damage to date; (b) trends in rates for property and casualty insurance and reinsurance; (c) the timely and full recoverability of reinsurance placed by R&Q with third parties, or other amounts due to R&Q; (d) changes in the projected amount of ceded reinsurance recoverables and the ratings and credit worthiness of reinsurers; (e) actual loss experience from insured or reinsured events and the timing of claims payments being faster or the receipt of reinsurance recoverables being slower than anticipated; (f) increased competition on the basis of pricing, capacity, coverage terms or other factors such as the increased inflow of third party capital into reinsurance markets, which could harm R&Q's ability to maintain or increase its business volumes or profitability; (g) greater frequency or severity of claims and loss activity than R&Q's underwriting, reserving or investment practices anticipated based on historical experience or industry data; (h) changes in the global financial markets, including the effects of inflation on R&Q's business, including on pricing and reserving, increased government involvement or intervention in the financial services industry and changes in interest rates, credit spreads, foreign currency exchange rates and future volatility in the world's credit, financial and capital markets that adversely affect the performance and valuation of R&Q's investments, financing plan and access to such markets or general financial condition; (i) changes in ratings, rating agency policies or practices; (j) the potential for changes to methodologies, estimations and assumptions that underlie the valuation of R&Q's financial instruments that could result in changes to investment valuations; (k) changes to R&Q's assessment as to whether it is more likely than not that it will be required to sell, or has the intent to sell, available-for-sale debt securities before their anticipated recovery; (l) the ability of R&Q's subsidiaries to pay dividends; (m) the potential effect of legislative or regulatory developments in the jurisdictions in which R&Q operates, such as those that could impact the financial markets or increase their respective business costs and required capital levels, including but not limited to changes in regulatory capital balances that must be maintained by operating subsidiaries and governmental actions for the purpose of stabilising the financial markets; (n) the actual amount of new and renewal business and acceptance of products and services, including new products and services and the materialisation of risks related to such products and services; (o) changes in applicable tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof; (p) the effects of mergers, acquisitions, divestitures and retrocession.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIBDBSUBDGXX
Date   Source Headline
24th Apr 20245:40 pmRNSUpdate on proposed sale of Accredited
19th Apr 20247:00 amRNSAppointment of Non-Executive Directors
12th Apr 20247:00 amRNSUpdate on Trading and Sale of Accredited
12th Mar 20242:33 pmRNSTR-1: Notification of major holdings
1st Mar 20247:00 amRNSComment on recent press speculation
11th Jan 20244:01 pmRNSShareholders approve sale of Accredited
4th Jan 20244:27 pmRNSIncrease in the number of Treasury Shares
2nd Jan 20247:00 amRNSRetirement of Alan Quilter
22nd Dec 20237:00 amRNSUpdate on discussions with the BMA
21st Dec 202311:12 amRNSTR-1: Notification of major holdings
14th Dec 20237:00 amRNSPosting of Circular
16th Nov 20239:58 amRNSTR-1: Notification of major holdings
14th Nov 20237:00 amRNSUpdate on Proposed Sale of Accredited
27th Oct 20234:52 pmRNSPDMR/Director Shareholding and Total Voting Rights
26th Oct 20237:00 amRNSLoss Portfolio Transfer
26th Oct 20237:00 amRNSChange of External Auditor
20th Oct 20235:23 pmRNSProposed Sale of R&Q’s Program Management business
16th Oct 202310:59 amRNSTR-1: Notification of major holdings
29th Sep 20237:00 amRNSResults for the half year ended 30 June 2023
22nd Sep 20237:00 amRNSStatement re Press Comment
20th Sep 202311:55 amRNSTR-1: Notification of major holdings
20th Sep 202311:54 amRNSTR-1: Notification of major holdings
16th Aug 20233:36 pmRNSPDMR/Director Shareholding and Total Voting Rights
28th Jul 20233:18 pmRNSResult of Annual General Meeting
18th Jul 20233:22 pmRNSTR-1: Notification of major holdings
17th Jul 20237:00 amRNSAppointment of Non-Executive Director
30th Jun 202310:08 amRNSAppointment of Non-Executive Director
30th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
29th Jun 20237:00 amRNSResults for the year ended 31 December 2022
26th Jun 20237:00 amRNSAccredited receives independent AM Best Rating
12th Jun 20237:00 amRNSR&Q raises up to $60 million of new equity
6th Jun 20235:31 pmRNSTR-1: Notification of major holdings
5th Jun 202311:23 amRNSTR-1: Notification of major holdings
2nd Jun 20233:50 pmRNSTR-1: Notification of major holdings
16th May 20239:27 amRNSTR-1: Notification of major holdings
10th May 20232:30 pmRNSTR-1: Notification of major holdings
10th May 202311:26 amRNSTR-1: Notification of major holdings
4th Apr 20237:00 amRNSStrategic & Trading Update
31st Mar 20237:00 amRNSAppointment of Non-Executive Chairman
17th Mar 20237:00 amRNSCompletion of Tradesman Sale
3rd Mar 202312:16 pmRNSTR-1: Notification of major holdings
23rd Feb 20237:00 amRNSProgram Management Update and Sale of Tradesman
17th Jan 20237:00 amRNSProgram Management Update
12th Jan 20237:00 amRNSPDMR/Director Shareholding and Total Voting Rights
6th Jan 20237:00 amRNSJoint venture to acquire legacy liabilities
5th Dec 20227:00 amRNSLoss Portfolio Transfer
31st Oct 20227:00 amRNSQ3 2022 Program Management Update
19th Oct 20224:40 pmRNSSecond Price Monitoring Extn
19th Oct 20224:35 pmRNSPrice Monitoring Extension
18th Oct 20229:24 amRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.